Preference of medicine and patient-reported quality of life in community-treated schizophrenic patients receiving aripiprazole vs standard of care: results from the STAR study

European Psychiatry : the Journal of the Association of European Psychiatrists
D TaylorRonald N Marcus

Abstract

To evaluate quality of life and patient preference for schizophrenia treatment in a community based study comparing the use of aripiprazole to the standard of care (SOC). This open-label, 26-week, multi-centre, randomised study compared aripiprazole with SOC (olanzapine, quetiapine or risperidone) in patients with schizophrenia (DSM-IV-TR criteria). The primary effectiveness variable was the mean total score of the Investigator Assessment Questionnaire (IAQ) at Week 26. The outcome research variables included the Preference of Medicine (POM) questionnaire, the Quality of Life Scale (QLS), and the EuroQoL-5D (EQ-5D). The results from these outcome research variables are the focus of this paper addressing quality of life and patient preference. A total of 555 patients were randomised to receive aripiprazole (n=284) or SOC (n=271). The OC data at Week 26, reported that more respondents rated the study medication as 'much better' compared with their previous medication in the aripiprazole group versus SOC for patients (59% vs 35%, P<0.001) and caregivers (58% vs 30%, P=0.014). The improvement in QLS total score was also significantly greater in the aripiprazole group compared with SOC--mean change from baseline in QLS total score o...Continue Reading

References

Jan 1, 1984·Schizophrenia Bulletin·D W HeinrichsW T Carpenter
Nov 21, 1997·Medical Care·P Dolan
Nov 7, 2000·PharmacoEconomics·E Lindström, K Bingefors
May 21, 2003·Acta Psychiatrica Scandinavica. Supplementum·L PrietoUNKNOWN SOHO Study Group
Jun 11, 2003·Schizophrenia Bulletin·Josephine MauskopfDavid L Grainger
Feb 18, 2004·Current Medicinal Chemistry·C Simon SebastianPeter F Buckley
Nov 4, 2004·CNS Drugs·A George Awad, Lakshmi N P Voruganti
Jan 27, 2005·Social Psychiatry and Psychiatric Epidemiology·Christiane RoickMatthias C Angermeyer
Sep 21, 2005·The New England Journal of Medicine·Jeffrey A LiebermanUNKNOWN Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
Oct 19, 2006·Journal of Psychopharmacology·Henry A Nasrallah, Rob Lasser

❮ Previous
Next ❯

Citations

Jun 23, 2012·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·M FranzT Meyer
Jun 13, 2013·CNS Drugs·A George Awad, Lakshmi N P Voruganti
Nov 6, 2009·Current Opinion in Psychiatry·Yu-Tao XiangGabor S Ungvari
Apr 3, 2010·Neuropsychiatric Disease and Treatment·Izchak KohenSum Lam
Feb 13, 2016·Expert Opinion on Pharmacotherapy·Steven G Potkin, Adrian Preda
Jan 5, 2014·The Cochrane Database of Systematic Reviews·Priya KhannaJun Xia

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here